Industry

AJPC News ASPC News Community Community : Women in PC Industry Patient Care and Advocacy

NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER
NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER

THOUSAND OAKS, Calif., Nov. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data at the American Heart Association (AHA) Scientific Sessions 2026 that further strengthen the case for more intensive lowering of low-density lipoprotein cholesterol (LDL-C) with Repatha®... Continue Reading

Date posted11/9/2026


TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops
TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops

GALWAY, Ireland and SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral™ renal denervation (RDN) system. The study showed statistically... Continue Reading

Date posted11/3/2026


New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026

Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment Discontinuation Continue Reading

Date posted08/28/2026


American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary

American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction Continue Reading

Date posted04/8/2026


FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken

FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Continue Reading

Date posted04/1/2026


Corcept Presents Data from MOMENTUM Trial at American College of Cardiology
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Mar. 28, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the... Continue Reading

Date posted03/28/2026


BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC A
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC A

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions Continue Reading

Date posted03/23/2026


Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk...
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk...

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline Continue Reading

Date posted03/18/2026


Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research Continue Reading

Date posted03/16/2026


Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric
Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric

Chiesi Global Rare Diseases Announces FDA Approval of JUXTAPID® (lomitapide) Capsules for Pediatric Use in Homozygous Familial Hypercholesterolemia (HoFH) Continue Reading

Date posted03/3/2026


Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Continue Reading

Date posted03/3/2026


Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceride
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceride

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) Continue Reading

Date posted02/26/2026